Boston Scientific has started patient recruitment in a prospective, randomized Platinum China clinical trial to assess the safety and effectiveness of Promus Element Everolimus-Eluting Platinum Chromium Coronary Stent compared to the Taxus Liberte Paclitaxel-Eluting Coronary Stent.

Boston Scientific said in the trail, the assessment is done while treating patients with a single de novo atherosclerotic lesion.

The Promus Element Stent features a platinum chromium alloy and stent design, which combine to offer greater radial strength and flexibility while reducing stent recoil.

The stent geometry helps create consistent lesion coverage and drug distribution while improving deliverability, which is enhanced by an advanced catheter delivery system.

The higher density platinum chromium alloy provides superior visibility while permitting thinner struts compared to prior-generation stents.

Boston Scientific Cardiology Rhythm and Vascular executive vice president and group president Hank Kucheman said the advanced platinum chromium alloy and new balloon catheter offered in the Element Stent System represent improvements over prior-generation stents.